356 related articles for article (PubMed ID: 28295443)
1. Risk of Incident Antidepressant-Treated Depression Associated with Use of 5α-Reductase Inhibitors Compared with Use of α-Blockers in Men with Benign Prostatic Hyperplasia: A Population-Based Study Using the Clinical Practice Research Datalink.
Hagberg KW; Divan HA; Nickel JC; Jick SS
Pharmacotherapy; 2017 May; 37(5):517-527. PubMed ID: 28295443
[TBL] [Abstract][Full Text] [Related]
2. Drug or symptom-induced depression in men treated with alpha 1-blockers for benign prostatic hyperplasia? A nested case-control study.
Clifford GM; Farmer RD
Pharmacoepidemiol Drug Saf; 2002; 11(1):55-61. PubMed ID: 11998552
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia.
Zhang J; Latour CD; Olawore O; Pate V; Friedlander DF; Stürmer T; Jonsson Funk M; Jensen BC
JAMA Netw Open; 2023 Nov; 6(11):e2343299. PubMed ID: 37962887
[TBL] [Abstract][Full Text] [Related]
4. Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink.
Hagberg KW; Divan HA; Persson R; Nickel JC; Jick SS
BMJ; 2016 Sep; 354():i4823. PubMed ID: 27659058
[TBL] [Abstract][Full Text] [Related]
5. 5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia.
Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Richert-Boe K; Horwitz RI; Jacobsen SJ
Mayo Clin Proc; 2016 Dec; 91(12):1717-1726. PubMed ID: 28126151
[TBL] [Abstract][Full Text] [Related]
6. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
7. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
Azoulay L; Eberg M; Benayoun S; Pollak M
JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
[TBL] [Abstract][Full Text] [Related]
8. Long-term use of 5α-reductase inhibitors and the risk of male breast cancer.
Duijnhoven RG; Straus SM; Souverein PC; de Boer A; Bosch JL; Hoes AW; De Bruin ML
Cancer Causes Control; 2014 Nov; 25(11):1577-82. PubMed ID: 25135615
[TBL] [Abstract][Full Text] [Related]
9. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
10. Use of 5α-reductase inhibitors for benign prostate hypertrophy and risk of high grade prostate cancer: a French population-based study.
Scailteux LM; Rioux-Leclercq N; Vincendeau S; Balusson F; Nowak E; Oger E;
BJU Int; 2019 Feb; 123(2):293-299. PubMed ID: 30025199
[TBL] [Abstract][Full Text] [Related]
11. Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co-occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational study.
Ilo D; Raluy-Callado M; Graham-Clarke P; Sadasivan R; Birt J; Donaldson R; Zhu E; Kirby MG; Neasham D
Int J Clin Pract; 2015 Aug; 69(8):853-62. PubMed ID: 26011100
[TBL] [Abstract][Full Text] [Related]
12. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery.
Souverein PC; Erkens JA; de la Rosette JJ; Leufkens HG; Herings RM
Eur Urol; 2003 May; 43(5):528-34. PubMed ID: 12705998
[TBL] [Abstract][Full Text] [Related]
13. Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia.
Hagberg KW; Divan HA; Fang SC; Nickel JC; Jick SS
Clin Epidemiol; 2017; 9():83-91. PubMed ID: 28228662
[TBL] [Abstract][Full Text] [Related]
14. The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
Ayodele O; Cabral HJ; McManus D; Jick S
Clin Epidemiol; 2021; 13():661-673. PubMed ID: 34377032
[TBL] [Abstract][Full Text] [Related]
15. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of recent trends in treatment patterns among men with benign prostatic hyperplasia.
Kruep EJ; Goodwin BB; Chaudhari S
Am J Mens Health; 2013 May; 7(3):214-9. PubMed ID: 23221685
[TBL] [Abstract][Full Text] [Related]
17. The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality.
Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Horwitz RI; Jacobsen SJ
Urology; 2018 Sep; 119():70-78. PubMed ID: 29906480
[TBL] [Abstract][Full Text] [Related]
18. The association of α-blockers and 5-α reductase inhibitors in benign prostatic hyperplasia with fractures.
Lim SY; Laengvejkal P; Panikkath R; Nugent K
Am J Med Sci; 2014 Jun; 347(6):463-71. PubMed ID: 24270079
[TBL] [Abstract][Full Text] [Related]
19. Long-term risk of benign prostatic hyperplasia-related surgery and acute urinary retention in men treated with 5-alpha reductase inhibitor versus alpha-blocker monotherapy in routine clinical care.
Bengtsen MB; Heide-Jørgensen U; Borre M; Nørgaard M
Prostate; 2023 Jul; 83(10):980-989. PubMed ID: 37057816
[TBL] [Abstract][Full Text] [Related]
20. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.
Ørsted DD; Bojesen SE; Nielsen SF; Nordestgaard BG
Eur Urol; 2011 Oct; 60(4):691-8. PubMed ID: 21705134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]